Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
IntroductionAcromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.ObjectivesTo assess the use of pasireotide and pegvisomant in...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2025-04-01
|
| シリーズ: | Frontiers in Endocrinology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1573721/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|